author = {Bubna, Aditya.}, title = {{Rituximab in dermatology: Revisited}}, journal ={Indian Journal of Drugs in Dermatology}, volume ={6}, number ={1}, pages = {5-12}, doi = {10.4103/ijdd.ijdd_9_19}, year = {2020}, abstract ={ Rituximab (RTX) is a specific mouse and human chimeric monoclonal antibody that has found to have numerous applications in dermatology. Though initially approved by the US FDA for treating rheumatoid arthritis and non-Hodgkin's lymphoma; currently its approval has extended to involve the pemphigus group of disorders; both as a first line drug as well as a therapeutic strategy for recalcitrant cases of pemphigus, unresponsive to conventional therapy. Apart from pemphigus, there have been a number of cutaneous disorders where rituximab has been found to be useful. This review will give a bird's eye view of the applications of rituximab in dermatology. }, URL ={https://www.ijdd.in/article.asp?issn=2455-3972;year=2020;volume=6;issue=1;spage=5;epage=12;aulast=Bubna;t=6}, eprint ={https://www.ijdd.in/article.asp?issn=2455-3972;year=2020;volume=6;issue=1;spage=5;epage=12;aulast=Bubna;t=6} }